Immunotherapy has already transformed cancer care, improving survival rates for conditions like melanoma and lung cancer. But research is now revealing its potential in non-cancer diseases.
-
Autoimmune Disorders: Immune “reprogramming” therapies are being tested in lupus, rheumatoid arthritis, and multiple sclerosis.
-
Infectious Diseases: Experimental vaccines and T-cell therapies are targeting persistent infections such as HIV and hepatitis.
-
Allergies: Desensitization immunotherapies may one day offer long-term relief for asthma and food allergies.
The global immunotherapy market is projected to exceed $250 billion by 2030, reflecting immense research investment. However, immune-related side effects, high treatment costs, and regulatory hurdles remain barriers to widespread use.
Still, the goal is clear to develop treatments that fine-tune, not just trigger, the immune system.
Can we safely expand the power of immunotherapy to every branch of medicine?
MBH/PS